Table 1. Patient Characteristics (N = 899).
No. (%) | P value | ||||
---|---|---|---|---|---|
Training (MDACC, n = 335) | Validation (MDACC, n = 96) | Internal test (MDACC, n = 48) | External test (BWH, n = 420) | ||
Age, median (range), y | 57 (24-83) | 58 (29-81) | 59.5 (41-87) | 59 (24-87) | .37a |
Sex | |||||
Female | 41 (12.2) | 16 (16.7) | 8 (16.7) | 75 (17.9) | .32b |
Male | 291 (86.9) | 80 (83.3) | 40 (83.3) | 344 (81.9) | |
Unspecified | 3 (0.9) | 0 | 0 | 1 (0.2) | |
Smoking status | |||||
Current | 68 (20.3) | 19 (19.8) | 11 (22.9) | 55 (13.1) | <.001b |
Former | 95 (28.4) | 40 (41.7) | 17 (35.4) | 217 (51.7) | |
Never | 103 (30.7) | 33 (34.4) | 17 (35.4) | 145 (34.5) | |
Unspecified | 67 (20.0) | 4 (4.2) | 3 (6.2) | 3 (0.7) | |
Primary cancer site | |||||
Oropharynx | 309 (92.2) | 92 (95.8) | 45 (93.8) | 314 (74.8) | <.001b |
Nasopharynx | 1 (0.3) | 0 | 0 | 0 | |
Larynx or hypopharynx | 2 (0.6) | 0 | 0 | 76 (18.1) | |
Oral cavity | 2 (0.6) | 0 | 0 | 0 | |
Unknown or other | 19 (5.7) | 4 (4.2) | 3 (6.2) | 30 (7.1) | |
AJCC stage | |||||
I | 3 (0.9) | 1 (1.0) | 0 | 12 (2.9) | .001b |
II | 11 (3.3) | 3 (3.1) | 2 (4.2) | 34 (8.1) | |
III | 42 (12.5) | 16 (16.7) | 12 (25.0) | 75 (17.9) | |
IV | 266 (79.4) | 72 (75.0) | 31 (64.6) | 295 (70.2) | |
Unspecified | 13 (3.9) | 4 (4.2) | 3 (6.2) | 4 (1.0) | |
HPV p16 statusc | |||||
Negative | 19 (5.7) | 9 (9.4) | 9 (18.8) | 49 (11.7) | <.001b |
Positive | 98 (29.3) | 76 (79.2) | 36 (75.0) | 224 (53.3) | |
Unspecified | 218 (65.1) | 11 (11.5) | 3 (6.2) | 147 (35.0) | |
T stage | |||||
T0 | 2 (0.6) | 0 | 0 | 0 | .24b |
T1 | 56 (16.7) | 20 (20.8) | 11 (22.9) | 89 (21.2) | |
T2 | 143 (42.7) | 35 (36.5) | 17 (35.4) | 160 (38.1) | |
T3 | 77 (23.0) | 22 (22.9) | 10 (20.8) | 109 (26.0) | |
T4 | 44 (13.1) | 15 (15.6) | 7 (14.6) | 57 (13.6) | |
Unspecified | 13 (3.9) | 4 (4.2) | 3 (6.2) | 5 (1.2) | |
N stage | |||||
N0 | 33 (9.9) | 9 (9.4) | 5 (10.4) | 85 (20.2) | <.001b |
N1 | 31 (9.3) | 13 (13.5) | 9 (18.8) | 52 (12.4) | |
N2 | 246 (74.3) | 68 (70.8) | 31 (64.6) | 247 (58.8) | |
N3 | 12 (3.6) | 2 (2.1) | 0 | 31 (7.4) | |
Unspecified | 13 (3.9) | 4 (4.2) | 3 (6.2) | 5 (1.2) |
Abbreviations: AJCC, American Joint Committee on Cancer (7th ed); BWH, Brigham and Women’s Hospital; HPV, human papillomavirus; MDACC, MD Anderson Cancer Center.
Kruskal-Wallis rank sum test.
Fisher exact test for differences among the data sets.
Patients with nonoropharyngeal carcinoma who did not undergo HPV p16 testing were coded as negative, given the very low incidence of HPV p16-positive tumors in these disease sites.